Feasibility of sentinel lymph node biopsy in patients who had conversion of axillary lymph nodes from clinically positive to negative following neoadjuvant chemotherapy
- Author(s)
- Moo Hyun LEE; Jihyoung CHO; Sun Hee KANG
- Keimyung Author(s)
- Kang, Sun Hee; Lee, Moo Hyun; Cho, Ji Hyoung
- Department
- Dept. of Surgery (외과학)
- Journal Title
- 대한외과학회 학술대회 초록집
- Issued Date
- 2017
- Abstract
- Purpose :
Complete remission of axillary lymph node after neoadjuvant
chemotherapy (NAC) can be commonly observed. However, the
use of sentinel lymph node biopsy (SLNB) following NAC in patients
presenting with clinically positive lymph nodes remains controversial.
This study evaluated the feasibility of SLNB in patients who had
conversion of axillary nodes from clinically positive to negative
following NAC.
Method :
We reviewed the records of 26 patients who had breast cancer with
clinically axillary lymph node-positive status and negative conversion
after NAC, between 2010 and 2016. Of these, 11 patients underwent
axillary lymph node dissection (ALND) without SLNB, and 15 patients
underwent ALND following SLNB, regardless of its results. SLB was
performed using both blue dye and a radiolabeled colloid mapping
agent.
Result :
Complete disease regression of axillary lymph nodes in 65.4% (17 of
26 patients). The sentinel lymph node (SLN) identification rate was
86.7%(13 of 15 patients). The median number of retrieved SLNs was
1 (range, 1-3). Of 13 patients, 8 had negative SLNs on frozen section
analysis and had no additional metastasis in lymph nodes removed by
ALND. The false negative rate of SLNB after NAC was 0%.
Conclusions :
SLNB may be feasible in patients who had conversion of axillary
nodes from clinically positive to negative following NAC, regardless of
number of retrieved SLNs and may help reduce surgical morbidity by
avoiding the need for standard axillary lymph node dissection in these
patients.
- Authorize & License
-
- Authorize공개
- EmbargoForever
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.